Report cover image

Global Cancer Vaccines Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 197 Pages
SKU # APRC20556596

Description

Summary

According to APO Research, the global Cancer Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Cancer Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Cancer Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Cancer Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Cancer Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Cancer Vaccines market include Merck, Pfizer, Glaxosmithkline, Serum Institute of India, Sanpower Group, Sanofi Pasteur, CSL Limited and Astellas Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Cancer Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Cancer Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Cancer Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Cancer Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Cancer Vaccines sales, projected growth trends, production technology, application and end-user industry.

Cancer Vaccines Segment by Company

Merck
Pfizer
Glaxosmithkline
Serum Institute of India
Sanpower Group
Sanofi Pasteur
CSL Limited
Astellas Pharma
Cancer Vaccines Segment by Type

Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
Cancer Vaccines Segment by Application

Cervical Cancer
Prostate Cancer
Others
Cancer Vaccines Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Cancer Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Cancer Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Cancer Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Cancer Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Vaccines industry.
Chapter 3: Detailed analysis of Cancer Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Cancer Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Cancer Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Cancer Vaccines Sales Value (2020-2031)
1.2.2 Global Cancer Vaccines Sales Volume (2020-2031)
1.2.3 Global Cancer Vaccines Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Cancer Vaccines Market Dynamics
2.1 Cancer Vaccines Industry Trends
2.2 Cancer Vaccines Industry Drivers
2.3 Cancer Vaccines Industry Opportunities and Challenges
2.4 Cancer Vaccines Industry Restraints
3 Cancer Vaccines Market by Company
3.1 Global Cancer Vaccines Company Revenue Ranking in 2024
3.2 Global Cancer Vaccines Revenue by Company (2020-2025)
3.3 Global Cancer Vaccines Sales Volume by Company (2020-2025)
3.4 Global Cancer Vaccines Average Price by Company (2020-2025)
3.5 Global Cancer Vaccines Company Ranking (2023-2025)
3.6 Global Cancer Vaccines Company Manufacturing Base and Headquarters
3.7 Global Cancer Vaccines Company Product Type and Application
3.8 Global Cancer Vaccines Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Cancer Vaccines Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Cancer Vaccines Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Cancer Vaccines Market by Type
4.1 Cancer Vaccines Type Introduction
4.1.1 Preventive Cancer Vaccines
4.1.2 Therapeutic Cancer Vaccines
4.2 Global Cancer Vaccines Sales Volume by Type
4.2.1 Global Cancer Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Cancer Vaccines Sales Volume by Type (2020-2031)
4.2.3 Global Cancer Vaccines Sales Volume Share by Type (2020-2031)
4.3 Global Cancer Vaccines Sales Value by Type
4.3.1 Global Cancer Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Cancer Vaccines Sales Value by Type (2020-2031)
4.3.3 Global Cancer Vaccines Sales Value Share by Type (2020-2031)
5 Cancer Vaccines Market by Application
5.1 Cancer Vaccines Application Introduction
5.1.1 Cervical Cancer
5.1.2 Prostate Cancer
5.1.3 Others
5.2 Global Cancer Vaccines Sales Volume by Application
5.2.1 Global Cancer Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Cancer Vaccines Sales Volume by Application (2020-2031)
5.2.3 Global Cancer Vaccines Sales Volume Share by Application (2020-2031)
5.3 Global Cancer Vaccines Sales Value by Application
5.3.1 Global Cancer Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Cancer Vaccines Sales Value by Application (2020-2031)
5.3.3 Global Cancer Vaccines Sales Value Share by Application (2020-2031)
6 Cancer Vaccines Regional Sales and Value Analysis
6.1 Global Cancer Vaccines Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Cancer Vaccines Sales by Region (2020-2031)
6.2.1 Global Cancer Vaccines Sales by Region: 2020-2025
6.2.2 Global Cancer Vaccines Sales by Region (2026-2031)
6.3 Global Cancer Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Cancer Vaccines Sales Value by Region (2020-2031)
6.4.1 Global Cancer Vaccines Sales Value by Region: 2020-2025
6.4.2 Global Cancer Vaccines Sales Value by Region (2026-2031)
6.5 Global Cancer Vaccines Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Cancer Vaccines Sales Value (2020-2031)
6.6.2 North America Cancer Vaccines Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Cancer Vaccines Sales Value (2020-2031)
6.7.2 Europe Cancer Vaccines Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Cancer Vaccines Sales Value (2020-2031)
6.8.2 Asia-Pacific Cancer Vaccines Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Cancer Vaccines Sales Value (2020-2031)
6.9.2 South America Cancer Vaccines Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Cancer Vaccines Sales Value (2020-2031)
6.10.2 Middle East & Africa Cancer Vaccines Sales Value Share by Country, 2024 VS 2031
7 Cancer Vaccines Country-level Sales and Value Analysis
7.1 Global Cancer Vaccines Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Cancer Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Cancer Vaccines Sales by Country (2020-2031)
7.3.1 Global Cancer Vaccines Sales by Country (2020-2025)
7.3.2 Global Cancer Vaccines Sales by Country (2026-2031)
7.4 Global Cancer Vaccines Sales Value by Country (2020-2031)
7.4.1 Global Cancer Vaccines Sales Value by Country (2020-2025)
7.4.2 Global Cancer Vaccines Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.5.2 USA Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Canada Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.8.2 Germany Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.9.2 France Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.9.3 France Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.11.2 Italy Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.12.2 Spain Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.13.2 Russia Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.16.2 China Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.16.3 China Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.17.2 Japan Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.19.2 India Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.19.3 India Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.20.2 Australia Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.24.2 Chile Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.26.2 Peru Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.28.2 Israel Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.29.2 UAE Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.31.2 Iran Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Cancer Vaccines Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Cancer Vaccines Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Cancer Vaccines Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Merck
8.1.1 Merck Comapny Information
8.1.2 Merck Business Overview
8.1.3 Merck Cancer Vaccines Sales, Value and Gross Margin (2020-2025)
8.1.4 Merck Cancer Vaccines Product Portfolio
8.1.5 Merck Recent Developments
8.2 Pfizer
8.2.1 Pfizer Comapny Information
8.2.2 Pfizer Business Overview
8.2.3 Pfizer Cancer Vaccines Sales, Value and Gross Margin (2020-2025)
8.2.4 Pfizer Cancer Vaccines Product Portfolio
8.2.5 Pfizer Recent Developments
8.3 Glaxosmithkline
8.3.1 Glaxosmithkline Comapny Information
8.3.2 Glaxosmithkline Business Overview
8.3.3 Glaxosmithkline Cancer Vaccines Sales, Value and Gross Margin (2020-2025)
8.3.4 Glaxosmithkline Cancer Vaccines Product Portfolio
8.3.5 Glaxosmithkline Recent Developments
8.4 Serum Institute of India
8.4.1 Serum Institute of India Comapny Information
8.4.2 Serum Institute of India Business Overview
8.4.3 Serum Institute of India Cancer Vaccines Sales, Value and Gross Margin (2020-2025)
8.4.4 Serum Institute of India Cancer Vaccines Product Portfolio
8.4.5 Serum Institute of India Recent Developments
8.5 Sanpower Group
8.5.1 Sanpower Group Comapny Information
8.5.2 Sanpower Group Business Overview
8.5.3 Sanpower Group Cancer Vaccines Sales, Value and Gross Margin (2020-2025)
8.5.4 Sanpower Group Cancer Vaccines Product Portfolio
8.5.5 Sanpower Group Recent Developments
8.6 Sanofi Pasteur
8.6.1 Sanofi Pasteur Comapny Information
8.6.2 Sanofi Pasteur Business Overview
8.6.3 Sanofi Pasteur Cancer Vaccines Sales, Value and Gross Margin (2020-2025)
8.6.4 Sanofi Pasteur Cancer Vaccines Product Portfolio
8.6.5 Sanofi Pasteur Recent Developments
8.7 CSL Limited
8.7.1 CSL Limited Comapny Information
8.7.2 CSL Limited Business Overview
8.7.3 CSL Limited Cancer Vaccines Sales, Value and Gross Margin (2020-2025)
8.7.4 CSL Limited Cancer Vaccines Product Portfolio
8.7.5 CSL Limited Recent Developments
8.8 Astellas Pharma
8.8.1 Astellas Pharma Comapny Information
8.8.2 Astellas Pharma Business Overview
8.8.3 Astellas Pharma Cancer Vaccines Sales, Value and Gross Margin (2020-2025)
8.8.4 Astellas Pharma Cancer Vaccines Product Portfolio
8.8.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Cancer Vaccines Value Chain Analysis
9.1.1 Cancer Vaccines Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Cancer Vaccines Sales Mode & Process
9.2 Cancer Vaccines Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Cancer Vaccines Distributors
9.2.3 Cancer Vaccines Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.